Could a Pre-Surgery drug shrink kidney tumors?

NCT ID NCT04022343

Ongoing Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing whether the drug cabozantinib can shrink tumors in 22 people with advanced kidney cancer before they have surgery. The goal is to see if the drug reduces tumor size enough to improve surgical outcomes and delay cancer return. Participants take cabozantinib by mouth before their scheduled operation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib (a drug that blocks enzymes needed for tumor growth)
What this could lead to: If successful, this could show that taking cabozantinib before surgery helps shrink kidney tumors and delays cancer recurrence.
What could go wrong: This is a small, early-phase trial with only 22 participants, so results may not apply to everyone. Cabozantinib can cause side effects like fatigue, diarrhea, and high blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nonpapillary renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CLEAR CELL RENAL CELL CARCINOMA RENAL CELL CARCINOMA STAGE III RENAL CELL CANCER AJCC V8

Contacts and locations

Locations

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.